{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:29:12Z","timestamp":1786649352738,"version":"build-2736575974"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"\n Background:<\/jats:title>\n \n Molecular monitoring of chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors at various time points after diagnosis is indispensable for therapeutic stratification. Thus, standardization and reproducibility of these tests to an international scale are of paramount importance. Standard TRUPCR BCR-ABL1 by quantitative real-time reverse transcription\u2013polymerase chain reaction and Xpert BCR-ABL Ultra performed on the Cepheid GeneXpert\n \u00ae<\/jats:sup>\n Instrument Systems (GeneXpert) were used to perform molecular monitoring in CML patients.\n <\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n Twenty-six samples (6 diagnostic and 20 monitoring samples) were tested on both platforms, and the BCR-ABL1 transcript ratio was compared. Kappa statistic was applied to calculate the agreement between the two tests, and Chi-square test was used to evaluate the difference in proportions in the two groups. The costs between the two tests were also compared, however, no statistical analysis was done for the same.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n All six diagnostic samples were detected by TRUPCR, but only four could be detected by GeneXpert. One of these was a minor BCR-ABL1 transcript (p190) which cannot be detected by GeneXpert. Among the 20 monitoring samples, there was moderate agreement between the two tests, with a\n P<\/jats:italic>\n = 0.01. The cost of TRUPCR was significantly less compared to GeneXpert.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n \n Standard BCR-ABL1 estimation by TRUPCR is superior and much more cost-effective than GeneXpert. GeneXpert inspite being an easy-to-use, fully automated platform lacks the benefit of customization with a high cost making the standard\n reverse transcription<\/jats:italic>\n \u2013\n polymerase chain reaction<\/jats:italic>\n techniques more feasible and usable for molecular monitoring in CML patients.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/jmau.jmau_88_23","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:00:11Z","timestamp":1758517211000},"page":"137-141","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Fully Automated GeneXpert BCR-ABL1 Assay versus Standard Nonautomated BCR-ABL1 Real-Time Reverse Transcription\u2013Polymerase Chain Reaction Quantitation: A Study from Tertiary Care Institute in India"],"prefix":"10.4103","volume":"13","author":[{"given":"Shilpi","family":"More","sequence":"first","affiliation":[{"name":"Department of Pathology, Employees\u2019 State Insurance Corporation Medical College and Hospital, Faridabad, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tathagata","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Department of Pathology, Employees\u2019 State Insurance Corporation Medical College and Hospital, Faridabad, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charu","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Pathology, Employees\u2019 State Insurance Corporation Medical College and Hospital, Faridabad, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukta","family":"Pujani","sequence":"additional","affiliation":[{"name":"Department of Pathology, Employees\u2019 State Insurance Corporation Medical College and Hospital, Faridabad, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj K.","family":"Chandoke","sequence":"additional","affiliation":[{"name":"Department of Pathology, Employees\u2019 State Insurance Corporation Medical College and Hospital, Faridabad, Haryana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"key":"R1-20260421","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/cncr.23427","article-title":"Molecular monitoring in chronic myeloid leukemia: Response to tyrosine kinase inhibitors and prognostic implications","volume":"112","author":"Jabbour","year":"2008","journal-title":"Cancer"},{"key":"R2-20260421","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"R3-20260421","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/s41375-022-01607-z","article-title":"Standardization of molecular monitoring of CML: Results and recommendations from the European treatment and outcome study","volume":"36","author":"White","year":"2022","journal-title":"Leukemia"},{"key":"R4-20260421","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","article-title":"Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg\/day of imatinib as initial therapy","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"key":"R5-20260421","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"R6-20260421","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"R7-20260421","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia","volume":"29","author":"Cross","year":"2015","journal-title":"Leukemia"},{"key":"R8-20260421","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"R9-20260421","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/01.moh.0000148551.93303.9e","article-title":"Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era","volume":"12","author":"Goldman","year":"2005","journal-title":"Curr Opin Hematol"},{"key":"R10-20260421","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia \u2013 A Europe against cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"R11-20260421","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2353\/jmoldx.2007.060112","article-title":"Evaluation of the Cepheid GeneXpert BCR-ABL assay","volume":"9","author":"Jobbagy","year":"2007","journal-title":"J Mol Diagn"},{"key":"R12-20260421","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3324\/haematol.2010.034389","article-title":"Cartridge-based automated BCR-ABL1 mRNA quantification: Solving the issues of standardization, at what cost?","volume":"96","author":"Cayuela","year":"2011","journal-title":"Haematologica"},{"key":"R13-20260421","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s12288-018-0933-1","article-title":"Laboratory monitoring of chronic myeloid leukemia in patients on tyrosine kinase inhibitors","volume":"34","author":"Chauhan","year":"2018","journal-title":"Indian J Hematol Blood Transfus"}],"container-title":["Journal of Microscopy and Ultrastructure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jmau.jmau_88_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:52:57Z","timestamp":1786647177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jmau.jmau_88_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jmau.jmau_88_23","relation":{},"ISSN":["2213-879X","2213-8803"],"issn-type":[{"value":"2213-879X","type":"print"},{"value":"2213-8803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,10]]},"assertion":[{"value":"2023-06-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}